

-> b reg
 FILE 'REGISTRY' ENTERED AT 13:00:39 ON 28 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 27 FEB 2008 HIGHEST RN 1005551-32-5
 DICTIONARY FILE UPDATES: 27 FEB 2008 HIGHEST RN 1005551-32-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.


Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndec/properties.html>

-> d que sta 113

L4 STR
 0~S~O 12 G1 Cb~O Cb~S
 9 @10 11 016 017 018 019
 C
 @8



VAR G1=O/S
 VAR G2=8/10
 REP G3={0-1} C
 VAR G4=CB/16-13 17-15/18-13 19-15
 NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RING(S) ARE ISOLATED OR EMBEDDED
 NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L6 154745 SEA FILE=REGISTRY ABB=ON PLU=ON NC2NC2/ES AND (NC5 OR NSC4
 OR NC6 OR NSC5)/ES
 L8 40 SEA FILE=REGISTRY SUB=L6 SSS FUL L4
 L10 408698 SEA FILE=REGISTRY ABB=ON PLU=ON (NSC3-C6 OR NCSC2-C6)/ES
 L12 58 SEA FILE=REGISTRY SUB=L10 SSS FUL L4
 L13 97 SEA FILE=REGISTRY ABB=ON PLU=ON (L8 OR L12)

-> b heap
 FILE 'HCAPIUS' ENTERED AT 13:00:49 ON 28 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is

held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Feb 2008 VOL 148 ISS 9
FILE LAST UPDATED: 27 Feb 2008 (20080227/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d bib abs hitstr l16 tot

-> d bib abs hitstr 119 tot

119 ASSESS 1 OF 36 NDA0165 COPYRIGHT 2008 ACS ON STM
 120 2007-12-05 NDA0165
 121 14112447
 122 Relative against anti-epileptogenic agent combinations for treatment of
 123 epilepsy
 124 Polymersystems, Michael R.; Wolfberg, Curt D.; Ruzumbe, Ganchei; Rhodes,
 125 Oregon
 126 Oregon Pharmaceutical, Inc., USA
 127 001 Int. Appl., 2 App
 128 CODED P2008
 129 Patent
 130 English
 131 PAR. DET 1

PATENT NO.		KIND	DATE	APPLICATION NO.	DATE
PT	NO-100712724	A2	10071219	100700-000003966	1007031
	NO-100712724	A1	10061018		
	HE, AL				

139 ASSAY 5 OF 36: HCA7L66 COPYRIGHT 2008 ACS on STM (Copyright)


139 ANSWER 5 OF 36 80A2186 C00Y8D88T 2008 ACS vs. 5TH (Cont.)

Absolute stereochemistry

118 *ANNALS & REC. OF. BRITISH ORIENTAL RESEARCH* 2000 VOL. 30, PART 1 CONTINUED[illegible]

3.19. ASSAULT 7 OF 14. BODILY CONTACT 2008 ACS no. 574 (Continued)

Abstract steroid(9H)N1C17.



261519-89-2 HCNPL000


Absolute stereochemistry

15	ANBARU 16 OF 16. EXAMPLES. COPYRIGHT 2008 ACH ON RTE				
16	2004.627400 ROARLES				
17	14313335				
18	Preparation of index as intermediates for psychotropic agents				
19	Am. HYDROLYZ. Benzol. Alkaloids				
20	Chemical Co. Ltd. Japan; Daicang Pharmaceutical Co. Ltd.				
21	2004.627400 ROARLES				
22	2004.627400 ROARLES				
23	2004.627400 ROARLES				
24	2004.627400 ROARLES				
25	2004.627400 ROARLES				
26	2004.627400 ROARLES				
27	2004.627400 ROARLES				
28	2004.627400 ROARLES				
29	2004.627400 ROARLES				
30	2004.627400 ROARLES				
31	2004.627400 ROARLES				
32	2004.627400 ROARLES				
33	2004.627400 ROARLES				
34	2004.627400 ROARLES				
35	2004.627400 ROARLES				
36	2004.627400 ROARLES				
37	2004.627400 ROARLES				
38	2004.627400 ROARLES				
39	2004.627400 ROARLES				
40	2004.627400 ROARLES				
41	2004.627400 ROARLES				
42	2004.627400 ROARLES				
43	2004.627400 ROARLES				
44	2004.627400 ROARLES				
45	2004.627400 ROARLES				
46	2004.627400 ROARLES				
47	2004.627400 ROARLES				
48	2004.627400 ROARLES				
49	2004.627400 ROARLES				
50	2004.627400 ROARLES				
51	2004.627400 ROARLES				
52	2004.627400 ROARLES				
53	2004.627400 ROARLES				
54	2004.627400 ROARLES				
55	2004.627400 ROARLES				
56	2004.627400 ROARLES				
57	2004.627400 ROARLES				
58	2004.627400 ROARLES				
59	2004.627400 ROARLES				
60	2004.627400 ROARLES				
61	2004.627400 ROARLES				
62	2004.627400 ROARLES				
63	2004.627400 ROARLES				
64	2004.627400 ROARLES				
65	2004.627400 ROARLES				
66	2004.627400 ROARLES				
67	2004.627400 ROARLES				
68	2004.627400 ROARLES				
69	2004.627400 ROARLES				
70	2004.627400 ROARLES				
71	2004.627400 ROARLES				
72	2004.627400 ROARLES				
73	2004.627400 ROARLES				
74	2004.627400 ROARLES				
75	2004.627400 ROARLES				
76	2004.627400 ROARLES				
77	2004.627400 ROARLES				
78	2004.627400 ROARLES				
79	2004.627400 ROARLES				
80	2004.627400 ROARLES				
81	2004.627400 ROARLES				
82	2004.627400 ROARLES				
83	2004.627400 ROARLES				
84	2004.627400 ROARLES				
85	2004.627400 ROARLES				
86	2004.627400 ROARLES				
87	2004.627400 ROARLES				
88	2004.627400 ROARLES				
89	200				

[illegible]

Absolute stereochemistry

119 ADVANCE 10 OF 36 SCAPED COPYRIGHT 2009 AOL OR ITS (C)001866-1



139 ANKWER 12 OF 16 NCALPLAS COPYRIGHT 1604 ACS ON STM
 AN 20060474833 NCALPLAS
 CN 14011317
 TI Method of treating mental disorders using 5 α and 5- β 2A antagonists,
 inverse agonists or partial agonists
 IN Wastine, Erik
 PA Belg.
 SO U.S. Pat. Appl. Publ., 14 pp.
 CODEN: INKCCD
 DA Patent
 LA English
 TAB:


[illegible][illegible][illegible]

12 267518-80-3, SM 1345
EL: D50 (Biological)
TX: (Therapeutic use
(as neuroleptic a
underlying dystro
using D5 and 5-HT
20 267518-80-3) HCAPL5

RE CNT 4 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

119 ANNNNN 12 OF 26 RECAPSULE COPYRIGHT 2008 ACD OR BTH (CONTINUED)
ON 6, *i*-Methano-10-isoindole-1,3(2H)-dione, 2-[(1H,2H)-2-[(4-(1,2-
benzothiazol-3-yl)-3-piperidinyl)methyl]cyclohexyl]methyl]benzohydro-
biphenylolone (1.13). (C₂₈H₂₈, 408, 765, 765) (CA INDEX NAME)

Absolute stereochemistry




● 824

A19 ANADIR 12 OF 16 READABLE COMMENT 2109 ACT ON RTR
 AN 2105 474536 READABLE
 TR 143:1315
 T1 Method of treating mental disorders using D1 and 5-HT2A antagonists,
 inverse agonists or partial agonists
 TR Bentzen, Erik
 TR Belg
 T2 U.S. Pat. Appl. Publ., 15 pp., CODE -in-part of U.S. Pat. No. 725,86
 CODED: 000000
 DT Patent
 LA English
 FAN 087 6

[illegible]


119 ANSWER 13 of 36 ECARLES COPYRIGHT 2004 A&S ON SYN (Continued)
 (as neuroleptic agent, augmenting therapeutic effect of) treating
 underlying dysregulation of emotional functionality of mental disorder
 using D4 and 5-HT2A antagonists, inverse agonists or partial agonist
 N3 347814-PR3 ECARLES
 C1 2-(4-METHOXY-2H-ISOINDOL-1,3(2H)-DIONE, 2-[11H,2H]-2-[4-(1,2-
 BENZISOTIAZOL-3-YL)-3-PICOLYL]METHYL]CYCLOHEXYLMETHYL]AMINOHYDRO-

Absolute stereochemistry



● 821

119 ANKER 14 05 06 NCARLAS COPYRIGHT 2004 ACS on STN
 AN 2058/59501 NCARLAS
 IN 1431198101
 120 Process for producing benzisothiazolipiperazinylmethylecyclohexylmet-
 yloheptanecarboxylate hydrochloride
 IN Kaitoku, Taro; Oda, Masumi
 121 Sanitomo Pharmaceuticals Co., Ltd., Japan
 50 PCT Int. Appl., 18 pp.
 CODES: P18X02
 122 Patent
 1A Japanese
 123 PAB.OUT 1

[illegible][illegible]

119 ANSWER 15 OF 26 NCLEXS COPYRIGHT 2008 ACS ON STM (Continued)

AN 11911740 NCLEXS

DN 14778413

17 Preparation of 3-oxo-4-(4-oxo-1-phenylbutyl)piperazine on ketone-sensitive lipase (abstract) for the treatment of diabetes and related disorders

IN Hansen, Polgar, Glaser, De Jong, Johannes Cornelius, Janssen, Wim, Buijsse,

Jansen

PA Many molecules A/B, Dm

PC 107 Int. Appl. 1, 107 pp

PC 107A PEXED

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J

PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

PC 107P

PC 107Q

PC 107R

PC 107S

PC 107T

PC 107U

PC 107V

PC 107W

PC 107X

PC 107Y

PC 107Z

PC 107A

PC 107B

PC 107C

PC 107D

PC 107E

PC 107F

PC 107G

PC 107H

PC 107I

PC 107J


PC 107K

PC 107L

PC 107M

PC 107N

PC 107O

R2C1=CC(=C(C=C1)N2C(=O)N3CCN(CC3)A[R6])C(=O)N2C(=O)N3CCN(CC3)A[R6]

A8 Title compound: ibuprofen A1, R₁ = H, amino, halo; substituted OH, sulfonyl, alkyl, alkoxy, acetyl, heterocycloalkyl or heterocycloalkenyl; X = N or OR; Y = M or CH₂; Z = N or CH₂, provided that X and Y are not all CH₂-R(3)-N = N, F, substituted OH, amino, sulfonyl, alkyl, alkoxy, heterocycloalkyl, cyclopentadienyl or heterocyclohexadienyl; R(1) = hydrogen, cyano, nitro, halogen, C(CH₃)=O, COCH₃, or CH(R)(C); with some enantiomers or pharmaceutically acceptable salts, tautomeric forms, and stereoisomers thereof were prepared as inhibitors of hormone-sensitive lipase (HSL). Also disclosed are prodrugs of the compounds. Compounds I and II are the parents of E for various treatments: (E)-hydroxy-4-(4-isobutyl-5-hydroxypentyl)-[2,3'-bisphosphoryl]-3,6-dienol with phosphonate followed by coupling with


119 ANSWER 14 OF 36 EXAMPLES COPYRIGHT 2009 ASG ON GTN (Continued)
L-[[pyridin-2-yl)methyl]piperazine in the presence of DMSO in CHCl₃ gave
compound 17, which showed 64% inhibition of HSL at a concn. of 10 μ M.
Thus, I and pharmaceutical congeners thereof are useful for the treatment
and/or prevention of medical disorders in which lowering of the activity
of hormone-sensitive lipase is desired, such as diabetes and dyslipidemia

[illegible]

```

      (drug candidate) preparation of piperazine carbamates as hormone-sensitive
      lipase inhibitors!
NOI  91120-48-6  SCAMUS
CS   1-[4-(carboxylic acid, 4-[(2-(2-piperidinyl)ethyl)-,
      4-[2-(4,4-dimethyl-2,6-dioxo-1-piperidinyl)ethyl]phenyl ester (CA INDEX

```




119 ANNNNN 26 OF 36 NCAPLUG C00PMCHT 2508 ACS on GTS (Continued)

RE #11420-70-9 NCAPLUG

CS 1-Piperazinecarboxylic acid, 4-[(2-[2-pyridinyl]ethyl)-, 4-[[2-[(4,4-dimethyl-1,3-dioxol-1-yl)pyridinyl]ethyl]phenyl ester, mono(2-trifluoroacetate) (XCI) (CA INDEX NAME)


DOI 10.1002/for




CRH 2
CRH 74-05-2
CRH 02 11 13 03



EN 011420-40-0 HCAPLOS
 CN 1-Piperazinecarboxylic acid, 4-(1-pyridinylmethyl)-, 4-(2-(4,4-dimethyl-




HS #11426-50-7 HCAPLUG
 CS 1-Piperazinecarboxylic acid, 4-(4-pyrimidinylmethyl)-,
 8-[2-(4,4-dimethyl-2,4-dioxo-1-piperidinyl)ethyl]phenyl ester (CA INDEX




UN 21424-51-9 HCAPLAD
CN 1-Piperazinecarboxylic acid, 4-(pyrazinylmethyl)-, 6-[2-(4,6-dimethyl-2,4-dioxo-1-piperidinylethyl)phenyl ester (SC) (CA INDEX NAME)


119 ANSWER 14 OF 36 RECAPLES COPYRIGHT 2008 ACS on STM (Continued)




HN E1313-42-0 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)



HN E1313-43-0 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




HN E1313-54-1 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)



HN E1313-65-2 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)

119 ANSWER 14 OF 36 RECAPLES COPYRIGHT 2008 ACS on STM (Continued)




PAGE 1-A




PAGE 2-A




HN E1313-65-9 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




HN E1313-61-0 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




119 ANSWER 14 OF 36 RECAPLES COPYRIGHT 2008 ACS on STM (Continued)




HN E1313-56-3 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)



HN E1313-57-6 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




HN E1313-58-5 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




HN E1313-59-4 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




119 ANSWER 14 OF 36 RECAPLES COPYRIGHT 2008 ACS on STM (Continued)




HN E1313-62-3 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)




HN E1313-63-3 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)



HN E1313-64-5 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)



HN E1313-66-9 RECAPLES
CN 1-piperazinomethanoylic acid, 4-[(2-{(4-methyl-2-pyridinyl)ethyl})-6-(2-{(4,6-dimethyl-2,6-dioxo-1-piperidinyl)ethyl}phenyl) ester (CA INDEX NAME)



114 NUMBER 19 OF 26 KEMPLER COPYRIGHT 2006 ACS on STM

AS 2003-0231633 KEMPLER

ON 131/133516

IT Valproic compound-derivative antiepileptic agent combination therapy for

treatment of schizophrenia

US General Electric, Kenneth W. Gilchrist, Adamson S.; Teoy, Katherine A.

US Abbott Laboratories, USA

US 02/ Jan. Appl. 19 pp.

US CLASS. F102D

US Patent

US English

FAS CH 1

FAS CH 2

FAS CH 3

FAS CH 4

FAS CH 5

FAS CH 6

FAS CH 7

FAS CH 8

FAS CH 9

FAS CH 10

FAS CH 11

FAS CH 12

FAS CH 13

FAS CH 14

FAS CH 15

FAS CH 16

FAS CH 17

FAS CH 18

FAS CH 19

FAS CH 20

FAS CH 21

FAS CH 22

FAS CH 23

FAS CH 24

FAS CH 25

FAS CH 26

FAS CH 27

FAS CH 28

FAS CH 29

FAS CH 30

FAS CH 31

FAS CH 32

FAS CH 33

FAS CH 34

FAS CH 35

FAS CH 36

FAS CH 37

FAS CH 38

FAS CH 39

FAS CH 40

FAS CH 41

FAS CH 42

FAS CH 43

FAS CH 44

FAS CH 45

FAS CH 46

FAS CH 47

FAS CH 48

FAS CH 49

FAS CH 50

FAS CH 51

FAS CH 52

FAS CH 53

FAS CH 54

FAS CH 55

FAS CH 56

FAS CH 57

FAS CH 58

FAS CH 59

FAS CH 60

FAS CH 61

FAS CH 62

FAS CH 63

FAS CH 64

FAS CH 65

FAS CH 66

FAS CH 67

FAS CH 68

FAS CH 69

FAS CH 70

FAS CH 71

FAS CH 72

FAS CH 73

FAS CH 74

FAS CH 75

FAS CH 76

FAS CH 77

FAS CH 78

FAS CH 79

FAS CH 80

FAS CH 81

FAS CH 82

FAS CH 83

FAS CH 84

FAS CH 85

FAS CH 86

FAS CH 87

FAS CH 88

FAS CH 89

FAS CH 90

FAS CH 91

FAS CH 92

FAS CH 93

FAS CH 94

FAS CH 95

FAS CH 96

FAS CH 97

FAS CH 98

FAS CH 99

FAS CH 100

FAS CH 101

FAS CH 102

FAS CH 103

FAS CH 104

FAS CH 105

FAS CH 106

FAS CH 107

FAS CH 108

FAS CH 109

FAS CH 110

FAS CH 111

FAS CH 112

FAS CH 113

FAS CH 114

FAS CH 115

FAS CH 116

FAS CH 117

FAS CH 118

FAS CH 119

FAS CH 120

FAS CH 121

FAS CH 122

FAS CH 123

FAS CH 124

FAS CH 125

FAS CH 126

FAS CH 127

FAS CH 128

FAS CH 129

FAS CH 130

FAS CH 131

FAS CH 132

FAS CH 133

FAS CH 134

FAS CH 135

FAS CH 136

FAS CH 137

FAS CH 138

FAS CH 139

FAS CH 140

FAS CH 141

FAS CH 142

FAS CH 143

FAS CH 144

FAS CH 145

FAS CH 146

FAS CH 147

FAS CH 148

FAS CH 149

FAS CH 150

FAS CH 151

FAS CH 152

FAS CH 153

FAS CH 154

FAS CH 155

FAS CH 156

FAS CH 157

FAS CH 158

FAS CH 159

FAS CH 160

FAS CH 161

FAS CH 162

FAS CH 163

FAS CH 164

FAS CH 165

FAS CH 166

FAS CH 167

FAS CH 168

FAS CH 169

FAS CH 170

FAS CH 171

FAS CH 172

FAS CH 173

FAS CH 174

FAS CH 175

FAS CH 176

FAS CH 177

FAS CH 178

FAS CH 179

FAS CH 180

FAS CH 181

FAS CH 182

FAS CH 183

FAS CH 184

FAS CH 185

FAS CH 186

FAS CH 187

FAS CH 188

FAS CH 189

FAS CH 190

FAS CH 191

FAS CH 192

FAS CH 193

FAS CH 194

FAS CH 195

FAS CH 196

FAS CH 197

FAS CH 198

FAS CH 199

FAS CH 200

FAS CH 201

FAS CH 202

FAS CH 203

FAS CH 204

FAS CH 205

FAS CH 206

FAS CH 207

FAS CH 208

FAS CH 209

FAS CH 210

FAS CH 211

FAS CH 212

FAS CH 213

FAS CH 214

FAS CH 215

FAS CH 216

FAS CH 217

FAS CH 218

FAS CH 219

FAS CH 220

FAS CH 221

FAS CH 222

FAS CH 223

FAS CH 224

FAS CH 225

FAS CH 226

FAS CH 227

FAS CH 228

FAS CH 229

FAS CH 230

FAS CH 231

FAS CH 232

FAS CH 233

FAS CH 234

FAS CH 235

FAS CH 236

FAS CH 237

FAS CH 238

FAS CH 239

FAS CH 240

FAS CH 241

FAS CH 242

FAS CH 243

FAS CH 244

FAS CH 245

FAS CH 246

FAS CH 247

FAS CH 248

FAS CH 249

FAS CH 250

FAS CH 251

FAS CH 252

FAS CH 253

FAS CH 254

FAS CH 255

FAS CH 256

FAS CH 257

FAS CH 258

FAS CH 259

FAS CH 260

FAS CH 261

FAS CH 262

FAS CH 263

FAS CH 264

FAS CH 265

FAS CH 266

FAS CH 267

FAS CH 268

FAS CH 269

FAS CH 270

FAS CH 271

FAS CH 272

FAS CH 273

FAS CH 274

FAS CH 275

FAS CH 276

FAS CH 277

FAS CH 278

FAS CH 279

FAS CH 280

FAS CH 281

FAS CH 282

FAS CH 283

FAS CH 284

FAS CH 285

FAS CH 286

FAS CH 287

FAS CH 288

FAS CH 289

FAS CH 290

FAS CH 291

FAS CH 292

FAS CH 293

FAS CH 294

FAS CH 295

FAS CH 296

FAS CH 297

FAS CH 298

FAS CH 299

FAS CH 300

FAS CH 301

FAS CH 302

FAS CH 303

FAS CH 304

FAS CH 305

FAS CH 306

FAS CH 307

FAS CH 308

FAS CH 309

FAS CH 310

FAS CH 311

FAS CH 312

FAS CH 313

FAS CH 314

FAS CH 315

FAS CH 316

FAS CH 317

FAS CH 318

FAS CH 319

FAS CH 320

FAS CH 321

FAS CH 322

FAS CH 323

FAS CH 324

FAS CH 325

FAS CH 326

FAS CH 327

FAS CH 328

118 ARJIS001 10 OF 16 NCAP112 COPYRIGHT 2008 ACR OR ITS (CONTINUED)



119 AMEMBOK 21 OF 36 RECAPLED CONFIDENT 2609 AED GR NTH

AN 2002 246535 HOARFLOU
 OR 134 268164
 TI Oral compositions with favorable disintegration characteristics
 AU Fujihira, Kenji
 DA Senohara Pharmaceutical Company, Limited, Japan
 SO JCT Int. Appl., 49 pp.
 COCORN: P10002
 DT Patent
 LA Japanese
 FAH CRT 1

PT	PATENT NO.	RTNO	DATE	APPLICATION NO.	DATE
PT	NO-2010212446		NO102313-8	2010100-29001483	200012818-0
M	AB, AG, AL, AM, AT, AU, BA, BE, BG, BR, CA, CH, CN, CO, CR, CU, CY, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IL, IN, IT, JP, KR, LI, LU, LV, MC, MD, ME, MK, MN, MU, NL, NO, NZ, PA, PL, PT, RO, RU, SE, SI, SK, TR, TW, UA, US, VN, YU, ZA, ZW		NO, SE, SL, SI, TJ, UK, US, YU, ZA, ZW		
AS	NO-2010212447		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212448		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212449		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212450		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212451		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212452		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212453		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212454		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212455		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212456		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212457		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212458		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212459		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212460		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212461		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212462		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212463		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212464		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212465		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212466		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212467		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212468		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212469		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212470		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212471		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212472		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212473		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212474		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212475		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212476		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212477		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212478		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212479		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212480		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212481		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212482		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212483		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212484		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212485		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212486		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212487		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212488		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212489		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212490		NO102313-8	2010100-29001483	200012818-0
AS	NO-2010212491		NO102313-8	2010100-29001483	200012818-0</

3166 100% water-soluble composite containing a hardy water-soluble anionic (sugar
 3167 3168 3169 3170 3171 3172 3173 3174 3175 3176 3177 3178 3179 3180 3181 3182 3183 3184 3185 3186 3187 3188 3189 3190 3191 3192 3193 3194 3195 3196 3197 3198 3199 3200 3201 3202 3203 3204 3205 3206 3207 3208 3209 3210 3211 3212 3213 3214 3215 3216 3217 3218 3219 3220 3221 3222 3223 3224 3225 3226 3227 3228 3229 3230 3231 3232 3233 3234 3235 3236 3237 3238 3239 3240 3241 3242 3243 3244 3245 3246 3247 3248 3249 3250 3251 3252 3253 3254 3255 3256 3257 3258 3259 3260 3261 3262 3263 3264 3265 3266 3267 3268 3269 3270 3271 3272 3273 3274 3275 3276 3277 3278 3279 3280 3281 3282 3283 3284 3285 3286 3287 3288 3289 3290 3291 3292 3293 3294 3295 3296 3297 3298 3299 3300 3301 3302 3303 3304 3305 3306 3307 3308 3309 3310 3311 3312 3313 3314 3315 3316 3317 3318 3319 3320 3321 3322 3323 3324 3325 3326 3327 3328 3329 3330 3331 3332 3333 3334 3335 3336 3337 3338 3339 3340 3341 3342 3343 3344 3345 3346 3347 3348 3349 3350 3351 3352 3353 3354 3355 3356 3357 3358 3359 3360 3361 3362 3363 3364 3365 3366 3367 3368 3369 3370 3371 3372 3373 3374 3375 3376 3377 3378 3379 3380 3381 3382 3383 3384 3385 3386 3387 3388 3389 3390 3391 3392 3393 3394 3395 3396 3397 3398 3399 3400 3401 3402 3403 3404 3405 3406 3407 3408 3409 3410 3411 3412 3413 3414 3415 3416 3417 3418 3419 3420 3421 3422 3423 3424 3425 3426 3427 3428 3429 3430 3431 3432 3433 3434 3435 3436 3437 3438 3439 3440 3441 3442 3443 3444 3445 3446 3447 3448 3449 3450 3451 3452 3453 3454 3455 3456 3457 3458 3459 3460 3461 3462 3463 3464 3465 3466 3467 3468 3469 3470 3471 3472 3473 3474 3475 3476 3477 3478 3479 3480 3481 3482 3483 3484 3485 3486 3487 3488 3489 3490 3491 3492 3493 3494 3495 3496 3497 3498 3499 3500 3501 3502 3503 3504 3505 3506 3507 3508 3509 3510 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 3531 3532 3533 3534 3535 3536 3537 3538 3539 3540 3541 3542 3543 3544 3545 3546 3547 3548 3549 3550 3551 3552 3553 3554 3555 3556 3557 3558 3559 3560 3561 3562 3563 3564 3565 3566 3567 3568 3569 3570 3571 3572 3573 3574 3575 3576 3577 3578 3579 3580 3581 3582 3583 3584 3585 3586 3587 3588 3589 3590 3591 3592 3593 3594 3595 3596 3597 3598 3599 3600 3601 3602 3603 3604 3605 3606 3607 3608 3609 3610 3611 3612 3613 3614 3615 3616 3617 3618 3619 3620 3621 3622 3623 3624 3625 3626 3627 3628 3629 3630 3631 3632 3633 3634 3635 3636 3637 3638 3639 3640 3641 3642 3643 3644 3645 3646 3647 3648 3649 3650 3651 3652 3653 3654 3655 3656 3657 3658 3659 3660 3661 3662 3663 3664 3665 3666 3667 3668 3669 3670 3671 3672 3673 3674 3675 3676 3677 3678 3679 3680 3681 3682 3683 3684 3685 3686 3687 3688 3689 3690 3691 3692 3693 3694 3695 3696 3697 3698 3699 3700 3701 3702 3703 3704 3705 3706 3707 3708 3709 3710 3711 3712 3713 3714 3715 3716 3717 3718 3719 3720 3721 3722 3723 3724 3725 3726 3727 3728 3729 3730 3731 3732 3733 3734 3735 3736 3737 3738 3739 3740 3741 3742 3743 3744 3745 3746 3747 3748 3749 3750 3751 3752 3753 3754 3755 3756 3757 3758 3759 3760 3761 3762 3763 3764 3765 3766 3767 3768 3769 3770 3771 3772 3773 3774 3775 3776 3777 3778 3779 3780 3781 3782 3783 3784 3785 3786 3787 3788 3789 3790 3791 3792 3793 3794 3795 3796 3797 3798 3799 3800 3801 3802 3803 3804 3805 3806 3807 3808 3809 3810 3811 3812 3813 3814 3815 3816 3817 3818 3819 3820 3821 3822 3823 3824 3825 3826 3827 3828 3829 3830 3831 3832 3833 3834 3835 3836 3837 3838 3839 3840 3841 3842 3843 3844 3845 3846 3847 3848 3849 3850 3851 3852 3853 3854 3855 3856 3857 3858 3859 3860 3861 3862 3863 3864 3865 3866 3867 3868 3869 3870 3871 3872 3873 3874 3875 3876 3877 3878 3879 3880 3881 3882 3883 3884 3885 3886 3887 3888 3889 3890 3891 3892 3893 3894 3895 3896 3897 3898 3899 3900 3901 3902 3903 3904 3905 3906 3907 3908 3909 3910 3911 3912 3913 3914 3915 3916 3917 3918 3919 3920 3921 3922 3923 3924 3925 3926 3927 3928 3929 3930 3931 3932 3933 3934 3935 3936 3937 3938 3939 3940 3941 3942 3943 3944 3945 3946 3947 3948 3949 3950 3951 3952 3953 3954 3955 3956 3957 3958 3959 3960 3961 3962 3963 3964 3965 3966 3967 3968 3969 3970 3971 3972 3973 3974 3975 3976 3977 3978

Absolute stereochemistry.

119 ANSWER 21 OF 36 EXAMPLES COPYRIGHT 2004 ACS on SIM (Continued)



RE:ENT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

119 ANSWER 22 OF 36 BACPLUG COPYRIGHT 2004 ACS on STM

AN 2881362742 HOSAPLANS
 SN 135322122
 TI Coating agents for sustained-release oral preparations
 drugs
 IX Nishii, Hirotsuki; Kobayashi, Hirohisa, Otsuda, Kazuyuki
 PA Sankyo Pharmaceutical Co., Ltd., Japan
 SO OCT Int. Appl., 28 pp.
 CCHN: 616X02
 DT Patent
 LA Japanese


[illegible]

PVP, starch and silica. The granules were coated with a first composition containing Et cellulose, talc, tri-Et citrate, ethanol, and water, and then a second composition containing methacrylate copolymer, PVP, sacrose ester, Macrogol 6000, and water.

[T] 3a7614-07-2 3a7614-08-3
ML: TNS (Therapeutic use); MSL (Biological study); UMS (Uses)
(polymeric coating agents for sustained-release oral preps. contain
basic drugs)

CS 6,7-Methano-1H-isoindole-1,3(2H)-dione, 2-[[[1R,2R]-2-[[4-(1,3-benzisoxazol-3-yl)-1-piperidinyl]methyl]cyclohexyl]methyl]hexahydro-, (1aF, 6R, 7R) = (CA INDEX NAME)

Absolute stereochemistry.



4, 7-Methano-1H-isoindole-1, 2(2H)-dione, 2-[[[1F, 2R]-2-[[4-(1, 2-benzisothiazol-3-yl)-3-piperidinylmethyl]cyclohexyl]methoxy]benzohydroxybenzoylchloride (1:1). (Yield, 45, 35, 76%). (CA INDEX NAME)

Absolute stereochemistry.

L18 ANNEX 15 OF EC/AMEN COPYRIGHT 2009 ACT ON THE
 AN 1997 113115 BOARDS
 AN 126 157522
 TI Preparation of cyclic amide derivatives as psychotropics
 TS Tokaji, Hajnalka, Oono, Toshihiro, Kojima, Atsuyuki
 UR Sentomei Pharmaceutical Co., Ltd., Japan; Daiichi Pharmaceutical Co.,
 Ltd.
 ZO Jpn. Tokaji Hajnalka Oono, 14 pp.
 OOH: JECOM
 UT Kojima
 LA Japanese
 FAN ON 1

BAGS 1.0^a

119 ANSWER 25 OF 36 NCAPLES COPYRIGHT 2008 ACS on SYN (Continued)
BIGL (Biological study); PREP (Preparation); USSS (Uses)
[preps. of cyclic imide derivs. as psychotropes]
IN 146204-32-9 NCAPLES
CN 4, 7-Methano-2-methylindole-3, 3(2H)-dione, 2-[[2-[[4-(3, 5-bis(methoxycarbonyl)-5-yl)-3-glyoxyethyl]methyl]cyclohexyl]methyl]benzoyldro-5-hydroxy-
(2)(1H), 2H), 3-am, 4R, 5S, 7R, 8aH) - (JCI) ICA INDEX

C1CCN(C1)c2c3ccccc3c[nH]2


708 196204-32=0 HCAPIUS
CM 5, 7-METHANO-2H-ISODOLE-1, 2(3H)-DIONE, 2-[12-{[4-(2, 3-BENZOISOTHIAZOL-3-YL)-3-PYPERIDYL]METHYL}CYCLOHEXYLMETHYL]BENZHYDRO-5-HYDROXY-, MEMOXYCARBOOXYIDE, [2(17°, 28°), 3am, 4S, 5S, 7S, 7aa, 1m, 19CT], (CS, INDEX NAME)

c1ccc2c(c1)c(c3ccccc23)N4CCNCC4

● **60%**


194204-22-1 KCANFLEW
 4, 7-MetEster(2-oxocetate-2, 3(2H)-dione, 2-[[2-[[4-(2,2-bis(4-methyl-3-oxo-1-oxo-4-oxo-1,2,3,4-tetrahydro-1H-pyridin-5-yl)methyl]oxy)phenyl]methyl]hexahydro-2H-pyran-5-yl]-2-(1H-2H)-3-oxo-4H, 5H, 7H, 8a)- (9CI) (CA 157456, N4400)

119 ANSWER 25 OF 36 ROADMAP COPYRIGHT 2008 ACS on STD (Continued)



17	184204-38-49	BLM (Reactant); SHN (Synthetic preparation), SHBP (Preparation), RACV (Reactant or reagent) (preparation of cyclic imide derivative as psychotheropics)
18	184204-38-6	ICMULDS
19	4,7-Methano-18-(isoleuco-3,3[2H]-dione, 2-[12-(4-(3,2-benzisothiazol-3-yl)-1-piperazinyl)methyl]oxyethyl)methyl-5-(formylethyl)hexahydro-, (2R,3R,2'R,3',4',5',6',7',8',9',10',11',12',13',14',15',16',17',18',19',20',21',22',23',24',25',26',27',28',29',30',31',32',33',34',35',36',37',38',39',40',41',42',43',44',45',46',47',48',49',50',51',52',53',54',55',56',57',58',59',60',61',62',63',64',65',66',67',68',69',70',71',72',73',74',75',76',77',78',79',80',81',82',83',84',85',86',87',88',89',90',91',92',93',94',95',96',97',98',99',100',101',102',103',104',105',106',107',108',109',110',111',112',113',114',115',116',117',118',119',120',121',122',123',124',125',126',127',128',129',130',131',132',133',134',135',136',137',138',139',140',141',142',143',144',145',146',147',148',149',150',151',152',153',154',155',156',157',158',159',160',161',162',163',164',165',166',167',168',169',170',171',172',173',174',175',176',177',178',179',180',181',182',183',184',185',186',187',188',189',190',191',192',193',194',195',196',197',198',199',200',201',202',203',204',205',206',207',208',209',210',211',212',213',214',215',216',217',218',219',220',221',222',223',224',225',226',227',228',229',230',231',232',233',234',235',236',237',238',239',240',241',242',243',244',245',246',247',248',249',250',251',252',253',254',255',256',257',258',259',260',261',262',263',264',265',266',267',268',269',270',271',272',273',274',275',276',277',278',279',280',281',282',283',284',285',286',287',288',289',290',291',292',293',294',295',296',297',298',299',300',301',302',303',304',305',306',307',308',309',310',311',312',313',314',315',316',317',318',319',320',321',322',323',324',325',326',327',328',329',330',331',332',333',334',335',336',337',338',339',340',341',342',343',344',345',346',347',348',349',350',351',352',353',354',355',356',357',358',359',360',361',362',363',364',365',366',367',368',369',370',371',372',373',374',375',376',377',378',379',380',381',382',383',384',385',386',387',388',389',390',391',392',393',394',395',396',397',398',399',400',401',402',403',404',405',406',407',408',409',410',411',412',413',414',415',416',417',418',419',420',421',422',423',424',425',426',427',428',429',430',431',432',433',434',435',436',437',438',439',440',441',442',443',444',445',446',447',448',449',450',451',452',453',454',455',456',457',458',459',460',461',462',463',464',465',466',467',468',469',470',471',472',473',474',475',476',477',478',479',480',481',482',483',484',485',486',487',488',489',490',491',492',493',494',495',496',497',498',499',500',501',502',503',504',505',506',507',508',509',510',511',512',513',514',515',516',517',518',519',520',521',522',523',524',525',526',527',528',529',530',531',532',533',534',535',536',537',538',539',540',541',542',543',544',545',546',547',548',549',550',551',552',553',554',555',556',557',558',559',560',561',562',563',564',565',566',567',568',569',570',571',572',573',574',575',576',577',578',579',580',581',582',583',584',585',586',587',588',589',590',591',592',593',594',595',596',597',598',599',600',601',602',603',604',605',606',607',608',609',610',611',612',613',614',615',616',617',618',619',620',621',622',623',624',625',626',627',628',629',630',631',632',633',634',635',636',637',638',639',640',641',642',643',644',645',646',647',648',649',650',651',652',653',654',655',656',657',658',659',660',661',662',663',664',665',666',667',668',669',670',671',672',673',674',675',676',677',678',679',680',681',682',683',684',685',686',687',688',689',690',691',692',693',694',695',696',697',698',699',700',701',702',703',704',705',706',707',708',709',710',711',712',713',714',715',716',717',718',719',720',721',722',723',724',725',726',727',728',729',730',731',732',733',734',735',736',737',738',739',740',741',742',743',744',745',746',747',748',749',750',751',752',753',754',755',756',757',758',759',760',761',762',763',764',765',766',767',768',769',770',771',772',773',774',775',776',777',778',779',780',781',782',783',784',785',786',787',788',789',790',791',792',793',794',795',796',797',798',799',800',801',802',803',804',805',806',807',808',809',810',811',812',813',814',815',816',817',818',819',820',821',822',823',824',825',826',827',828',829',830',831',832',833',834',835',836',837',838',839',840',841',842',843',844',845',846',847',848',849',850',851',852',853',854',855',856',857',858',859',860',861',862',863',864',865',866',867',868',869',870',871',872',873',874',875',876',877',878',879',880',881',882',883',884',885',886',887',888',889',890',891',892',893',894',895',896',897',898',899',900',901',902',903',904',905',906',907',908',909',910',911',912',913',914',915',916',917',918',919',920',921',922',923',924',925',926',927',928',929',930',931',932',933',934',935',936',937',938',939',940',941',942',943',944',945',946',947',948',949',950',951',952',953',954',955',956',957',958',959',960',961',962',963',964',965',966',967',968',969',970',971',972',973',974',975',976',977',978',979',980',981',982',983',984',985',986',987',988',989',990',991',992',993',994',995',996',	

Relative stereochemistry.



—

18 MICR-
 139505-45-60 139505-47-40 139505-48-50
 139505-51-80 139505-52-40 139505-56-10
 139505-55-80 139505-56-50 139505-57-80
 139505-58-10 139505-59-20 139505-60-50
 139505-61-60 139505-66-10 139505-86-10

129505-92-49 129505-95-49 129506-02-89

Relative stereochemistry:

Relative stereochemistry

2.752.8025 1.752.8025 |

CN1CCN(C1)C2=NC3=CC=CC=C3N=C2C4=CC=CC=C4C5=CC=CC=C5C6=CC=CC=C6C7=CC=CC=C7C8=CC=CC=C8C9=CC=CC=C9C10=CC=CC=C10C11=CC=CC=C11C12=CC=CC=C12C13=CC=CC=C13C14=CC=CC=C14C15=CC=CC=C15C16=CC=CC=C16C17=CC=CC=C17C18=CC=CC=C18C19=CC=CC=C19C20=CC=CC=C20C21=CC=CC=C21C22=CC=CC=C22C23=CC=CC=C23C24=CC=CC=C24C25=CC=CC=C25C26=CC=CC=C26C27=CC=CC=C27C28=CC=CC=C28C29=CC=CC=C29C30=CC=CC=C30C31=CC=CC=C31C32=CC=CC=C32C33=CC=CC=C33C34=CC=CC=C34C35=CC=CC=C35C36=CC=CC=C36C37=CC=CC=C37C38=CC=CC=C38C39=CC=CC=C39C40=CC=CC=C40C41=CC=CC=C41C42=CC=CC=C42C43=CC=CC=C43C44=CC=CC=C44C45=CC=CC=C45C46=CC=CC=C46C47=CC=CC=C47C48=CC=CC=C48C49=CC=CC=C49C50=CC=CC=C50C51=CC=CC=C51C52=CC=CC=C52C53=CC=CC=C53C54=CC=CC=C54C55=CC=CC=C55C56=CC=CC=C56C57=CC=CC=C57C58=CC=CC=C58C59=CC=CC=C59C60=CC=CC=C60C61=CC=CC=C61C62=CC=CC=C62C63=CC=CC=C63C64=CC=CC=C64C65=CC=CC=C65C66=CC=CC=C66C67=CC=CC=C67C68=CC=CC=C68C69=CC=CC=C69C70=CC=CC=C70C71=CC=CC=C71C72=CC=CC=C72C73=CC=CC=C73C74=CC=CC=C74C75=CC=CC=C75C76=CC=CC=C76C77=CC=CC=C77C78=CC=CC=C78C79=CC=CC=C79C80=CC=CC=C80C81=CC=CC=C81C82=CC=CC=C82C83=CC=CC=C83C84=CC=CC=C84C85=CC=CC=C85C86=CC=CC=C86C87=CC=CC=C87C88=CC=CC=C88C89=CC=CC=C89C90=CC=CC=C90C91=CC=CC=C91C92=CC=CC=C92C93=CC=CC=C93C94=CC=CC=C94C95=CC=CC=C95C96=CC=CC=C96C97=CC=CC=C97C98=CC=CC=C98C99=CC=CC=C99C100=CC=CC=C100C101=CC=CC=C101C102=CC=CC=C102C103=CC=CC=C103C104=CC=CC=C104C105=CC=CC=C105C106=CC=CC=C106C107=CC=CC=C107C108=CC=CC=C108C109=CC=CC=C109C110=CC=CC=C110C111=CC=CC=C111C112=CC=CC=C112C113=CC=CC=C113C114=CC=CC=C114C115=CC=CC=C115C116=CC=CC=C116C117=CC=CC=C117C118=CC=CC=C118C119=CC=CC=C119C120=CC=CC=C120C121=CC=CC=C121C122=CC=CC=C122C123=CC=CC=C123C124=CC=CC=C124C125=CC=CC=C125C126=CC=CC=C126C127=CC=CC=C127C128=CC=CC=C128C129=CC=CC=C129C130=CC=CC=C130C131=CC=CC=C131C132=CC=CC=C132C133=CC=CC=C133C134=CC=CC=C134C135=CC=CC=C135C136=CC=CC=C136C137=CC=CC=C137C138=CC=CC=C138C139=CC=CC=C139C140=CC=CC=C140C141=CC=CC=C141C142=CC=CC=C142C143=CC=CC=C143C144=CC=CC=C144C145=CC=CC=C145C146=CC=CC=C146C147=CC=CC=C147C148=CC=CC=C148C149=CC=CC=C149C150=CC=CC=C150C151=CC=CC=C151C152=CC=CC=C152C153=CC=CC=C153C154=CC=CC=C154C155=CC=CC=C155C156=CC=CC=C156C157=CC=CC=C157C158=CC=CC=C158C159=CC=CC=C159C160=CC=CC=C160C161=CC=CC=C161C162=CC=CC=C162C163=CC=CC=C163C164=CC=CC=C164C165=CC=CC=C165C166=CC=CC=C166C167=CC=CC=C167C168=CC=CC=C168C169=CC=CC=C169C170=CC=CC=C170C171=CC=CC=C171C172=CC=CC=C172C173=CC=CC=C173C174=CC=CC=C174C175=CC=CC=C175C176=CC=CC=C176C177=CC=CC=C177C178=CC=CC=C178C179=CC=CC=C179C180=CC=CC=C180C181=CC=CC=C181C182=CC=CC=C182C183=CC=CC=C183C184=CC=CC=C184C185=CC=CC=C185C186=CC=CC=C186C187=CC=CC=C187C188=CC=CC=C188C189=CC=CC=C189C190=CC=CC=C190C191=CC=CC=C191C192=CC=CC=C192C193=CC=CC=C193C194=CC=CC=C194C195=CC=CC=C195C196=CC=CC=C196C197=CC=CC=C197C198=CC=CC=C198C199=CC=CC=C199C200=CC=CC=C200C201=CC=CC=C201C202=CC=CC=C202C203=CC=CC=C203C204=CC=CC=C204C205=CC=CC=C205C206=CC=CC=C206C207=CC=CC=C207C208=CC=CC=C208C209=CC=CC=C209C210=CC=CC=C210C211=CC=CC=C211C212=CC=CC=C212C213=CC=CC=C213C214=CC=CC=C214C215=CC=CC=C215C216=CC=CC=C216C217=CC=CC=C217C218=CC=CC=C218C219=CC=CC=C219C220=CC=CC=C220C221=CC=CC=C221C222=CC=CC=C222C223=CC=CC=C223C224=CC=CC=C224C225=CC=CC=C225C226=CC=CC=C226C227=CC=CC=C227C228=CC=CC=C228C229=CC=CC=C229C230=CC=CC=C230C231=CC=CC=C231C232=CC=CC=C232C233=CC=CC=C233C234=CC=CC=C234C235=CC=CC=C235C236=CC=CC=C236C237=CC=CC=C237C238=CC=CC=C238C239=CC=CC=C239C240=CC=CC=C240C241=CC=CC=C241C242=CC=CC=C242C243=CC=CC=C243C244=CC=CC=C244C245=CC=CC=C245C246=CC=CC=C246C247=CC=CC=C247C248=CC=CC=C248C249=CC=CC=C249C250=CC=CC=C250C251=CC=CC=C251C252=CC=CC=C252C253=CC=CC=C253C254=CC=CC=C254C255=CC=CC=C255C256=CC=CC=C256C257=CC=CC=C257C258=CC=CC=C258C259=CC=CC=C259C260=CC=CC=C260C261=CC=CC=C261C262=CC=CC=C262C263=CC=CC=C263C264=CC=CC=C264C265=CC=CC=C265C266=CC=CC=C266C267=CC=CC=C267C268=CC=CC=C268C269=CC=CC=C269C270=CC=CC=C270C271=CC=CC=C271C272=CC=CC=C272C273=CC=CC=C273C274=CC=CC=C274C275=CC=CC=C275C276=CC=CC=C276C277=CC=CC=C277C278=CC=CC=C278C279=CC=CC=C279C280=CC=CC=C280C281=CC=CC=C281C282=CC=CC=C282C283=CC=CC=C283C284=CC=CC=C284C285=CC=CC=C285C286=CC=CC=C286C287=CC=CC=C287C288=CC=CC=C288C289=CC=CC=C289C290=CC=CC=C290C291=CC=CC=C291C292=CC=CC=C292C293=CC=CC=C293C294=CC=CC=C294C295=CC=CC=C295C296=CC=CC=C296C297=CC=CC=C297C298=CC=CC=C298C299=CC=CC=C299C300=CC=CC=C300C301=CC=CC=C301C302=CC=CC=C302C303=CC=CC=C303C304=CC=CC=C304C305=CC=CC=C305C306=CC=CC=C306C307=CC=CC=C307C308=CC=CC=C308C309=CC=CC=C309C310=CC=CC=C310C311=CC=CC=C311C312=CC=CC=C312C313=CC=CC=C313C314=CC=CC=C314C315=CC=CC=C315C316=CC=CC=C316C317=CC=CC=C317C318=CC=CC=C318C319=CC=CC=C319C320=CC=CC=C320C321=CC=CC=C321C322=CC=CC=C322C323=CC=CC=C323C324=CC=CC=C324C325=CC=CC=C325C326=CC=CC=C326C327=CC=CC=C327C328=CC=CC=C328C329=CC=CC=C329C330=CC=CC=C330C331=CC=CC=C331C332=CC=CC=C332C333=CC=CC=C333C334=CC=CC=C334C335=CC=CC=C335C336=CC=CC=C336C337=CC=CC=C337C338=CC=CC=C338C339=CC=CC=C339C340=CC=CC=C340C341=CC=CC=C341C342=CC=CC=C342C343=CC=CC=C343C344=CC=CC=C344C345=CC=CC=C345C346=CC=CC=C346C347=CC=CC=C347C348=CC=CC=C348C349=CC=CC=C349C350=CC=CC=C350C351=CC=CC=C351C352=CC=CC=C352C353=CC=CC=C353C354=CC=CC=C354C355=CC=CC=C355C356=CC=CC=C356C357=CC=CC=C357C358=CC=CC=C358C359=CC=CC=C359C360

Balancing structuralism and

© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd

● **WCS**

bioRxiv preprint doi: <https://doi.org/10.1101/2019.05.20.256410>; this version posted May 20, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.

[illegible]

Estadística 2019

Environ Biol Fish (2008) 81:111–120


Relative Bioavailability

● 40

Relative stereochemistry

CN1CCN(C1)C2=CN3C=CC=CC=C3N2C[C@H](C4=CC=CC=C4)C5=CC=CC=C5relative stereochemistry
 22

119 ANSWER 33 OF 36 KNOXLES COPYRIGHT 2004 ACS OR STM (Continued)



RD 139505-42-5 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)



RD 139505-41-6 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)




RD 139505-44-3 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, hexahydro-2-[[2-[[4-(2-pyridinyl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)

Relative stereochemistry:

119 ANSWER 33 OF 36 KNOXLES COPYRIGHT 2004 ACS OR STM (Continued)


RD 139505-46-5 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)

Relative stereochemistry:



RD 139505-47-6 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)


Relative stereochemistry:



RD 139505-49-3 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)


Relative stereochemistry:

119 ANSWER 33 OF 36 KNOXLES COPYRIGHT 2004 ACS OR STM (Continued)




RD 139505-46-3 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)

Relative stereochemistry:



RD 139505-43-4 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)




119 ANSWER 33 OF 36 KNOXLES COPYRIGHT 2004 ACS OR STM (Continued)



● KCI

RD 139505-45-6 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)


Relative stereochemistry:



● KCI

RD 139506-60-4 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)


Relative stereochemistry:



RD 139506-63-4 KNOXLES
CN 4,7-Methano-10-oxabicyclo-[3,3,1]non-2-one, 2-[[2-[[4-(1,3-benzoxothiazol-3-yl)-1-piperidinyl]methoxy]phenyl]benzyl]benzyl (CA INDEX NAME)


119 ANSWER 32 OF 36 REAGLES COPYRIGHT 2008 ACS ON STM (Continued)

Relative stereochemistry:



13943-11-4 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, monohydrochloride, [2(10⁶,10⁶), 3a⁶, 7a⁶]- (NCI) (CA INDEX NAME)

Relative stereochemistry:




● RCI

13943-12-1 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]-, 4,5,7a-tetrahydro-, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)



13943-12-6 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-3-pyridyl)-1-piperidinyl]methyl]piperidinyl]methyl]-, [2(10⁶,10⁶), 3a⁶, 7a⁶]- (NCI) (CA INDEX NAME)

119 ANSWER 33 OF 36 REAGLES COPYRIGHT 2008 ACS ON STM (Continued)



CN 3

CN 67-82-4


CNF C3 88 84

Absolute stereochemistry:



13943-11-6 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, monohydrochloride, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)

Anastole (+) Absolute stereochemistry unknown.




● RCI

13943-22-1 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, monohydrochloride, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)

Relative stereochemistry:


119 ANSWER 33 OF 36 REAGLES COPYRIGHT 2008 ACS ON STM (Continued)

Relative stereochemistry:



13943-11-4 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, monohydrochloride, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)

Relative stereochemistry:



● RCI

13943-12-1 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)


CN 3

CNF 13943-18-2

CNF C33 83A 34 82 3

Rotation (+). Absolute stereochemistry unknown.


119 ANSWER 34 OF 36 REAGLES COPYRIGHT 2008 ACS ON STM (Continued)



● RCI

13943-11-4 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, monohydrochloride, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)

Relative stereochemistry:




● RCI


13943-12-1 REAGLES
 CN 4,7-Methano-3H-indole-1,3[2H]-dione, 2-[[2-[(4-1,2-benzisothiazol-3-yl)-1-piperidinyl]methyl]piperidinyl]methyl]benzoyl-, monohydrochloride, [2(10⁶,10⁶), 3a⁶, 5b⁶, 7a⁶]- (NCI) (CA INDEX NAME)

Relative stereochemistry:

119 ANSWER 33 OF 36 ROWS COPYRIGHT 2008 ACS OR STM (Continued)




13943-1-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)



13943-18-3 ROWS
 CN 18-Oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:




119 ANSWER 33 OF 36 ROWS COPYRIGHT 2008 ACS OR STM (Continued)




13943-41-1 ROWS
 CN 18-Oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:



13943-41-1 ROWS
 CN 18-Oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:




13943-41-1 ROWS
 CN 18-Oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:

119 ANSWER 33 OF 36 ROWS COPYRIGHT 2008 ACS OR STM (Continued)

13943-41-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)


Relative stereochemistry:



13943-41-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

13943-41-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:




13943-41-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:




119 ANSWER 33 OF 36 ROWS COPYRIGHT 2008 ACS OR STM (Continued)




13943-41-1 ROWS
 CN 18-Oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)

Relative stereochemistry:



13943-41-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)


Relative stereochemistry:



13943-41-1 ROWS
 CN 4,7-Methano-10-oxabicyclo-[3,2,0]hept-2-one, 2-[[3-[(4-(1,3-benzoxazol-3-yl)-1-piperidinyl)methyl]propyl]-(1,3)-bis(2-methylbenzoyl)-2-oxo-1,2,3,4-tetrahydronaphthalen-2-yl]-(1R,2R,3R,4R,5R,6R,7R,8R)- (RCI) (CA INDEX NAME)


Relative stereochemistry:

119 ANSWER 33 OF 26 KNOXLES COPYRIGHT 2008 ACS OR STM (Continued)




RE 184661-61-0 KNOXLES
 OR 4, 3-Methyl-2-oxo-1,3-dioxane-5-carboxamide, 2-[[2-[[4-(1,3-benzimidazol-2-yl)-1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

Relative stereochemistry



RE 184661-61-0 KNOXLES
 OR 4, 3-Methyl-2-oxo-1,3-dioxane-5-carboxamide, 2-[[2-[[4-(1,3-benzimidazol-2-yl)-1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

Relative stereochemistry




RE 184661-61-0 KNOXLES
 OR 4, 3-Methyl-2-oxo-1,3-dioxane-5-carboxamide, 2-[[2-[[4-(1,3-benzimidazol-2-yl)-1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

Relative stereochemistry

119 ANSWER 33 OF 26 KNOXLES COPYRIGHT 2008 ACS OR STM (Continued)

3-[1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

Relative stereochemistry



RE 184661-61-0 KNOXLES
 OR 3-Methyl-2-oxo-1,3-dioxane-5-carboxamide, 2-[[2-[[4-(1,3-benzimidazol-2-yl)-1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

Relative stereochemistry



119 ANSWER 34 OF 26 KNOXLES COPYRIGHT 2008 ACS OR STM


RE 184661-61-0 KNOXLES
 OR 3-Methyl-2-oxo-1,3-dioxane-5-carboxamide, 2-[[2-[[4-(1,3-benzimidazol-2-yl)-1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

119 ANSWER 34 OF 26 KNOXLES COPYRIGHT 2008 ACS OR STM (Continued)



PAGE 1-A



PAGE 1-A



PAGE 1-B



AS IMMEDIATE LINKED-SPIN-ACCEPTOR COMPOUND, which release a diffusible dye or dye precursor by a color reaction, was described for use in preparing piezoelectric transducer materials. Thus, a piezoelectric material was prepared by embedding a polyacrylate transducer substrate, exposed with an image acceptor layer, a white partition layer, a light absorbing layer, a piezoelectric layer (a 0.25 μm thick), a piezoelectric layer, a piezoelectric layer, and a piezoelectric layer. This material was then exposed, conducted with a piezoelectric layer, and processed to give a yellow change with a blue or red dye and a blue dye. The dye was 1,3,5-trisubstituted benzene with an electron donor group and a color forming material.

RE 184661-61-0 KNOXLES
 OR 3-Methyl-2-oxo-1,3-dioxane-5-carboxamide, 2-[[2-[[4-(1,3-benzimidazol-2-yl)-1-(2-oxo-1,3-dioxan-5-yl)ethyl]phenyl]ethyl]benzamide,
 [2(1R*,2R*),3am,4R,5R,6am] - (NCT) (CA 13084 NMR)

— (NCT) — (NCT)

-> d his

```

(FILE 'SINGUIDE' ENTERED AT 11:19:30 ON 28 FEB 2008)
  DEL HIS Y
FILE 'HCAPLUS' ENTERED AT 12:35:43 ON 28 FEB 2008
L1      1 US20060142276/PN
FILE 'REGISTRY' ENTERED AT 12:35:54 ON 28 FEB 2008
FILE 'HCAPLUS' ENTERED AT 12:35:54 ON 28 FEB 2008
L2      TRA L1 1- RN :      1 TERM
FILE 'REGISTRY' ENTERED AT 12:35:54 ON 28 FEB 2008
L3      1 SEA L2
L4      STR
L5      0 L4
L6      154745 NC2NC2/ES AND (NC5 OR NSC4 OR NC6 OR NSC5)/ES
L7      0 L4 SAM SUB=L6
L8      40 L4 FULL SUB=L6
        SAV TEM L8 J039C1/A
L9      0 L8 AND L3
L10     408698 (NSC3-C6 OR NCSC2-C6)/ES
L11     4 L4 SAM SUB=L10
L12     58 L4 FULL SUB=L10
        SAV TEM J039C1/A L12
L13     97 L8,L12
L14     1 L13 AND L3
L15     96 L13 NOT L14
FILE 'HCAPLUS' ENTERED AT 12:47:54 ON 28 FEB 2008
L16     2 L14
L17     36 L15
L18     32 L17 AND (PD<-20051222 OR AD<-20051222 OR PRD<-20051222)
L19     36 L17-18
FILE 'HCAOLD' ENTERED AT 13:00:19 ON 28 FEB 2008
L20     0 L13
->

```